Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 2Neoplasms, Plasma Cell 2Multiple Myeloma 2von Hippel-Lindau Disease 1Vipoma 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Meningioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Insulinoma 1Hemangiopericytoma, Malignant 1Hemangioblastoma 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

belzutifan 3gallium Ga 68 dotatate 2vatalanib 1tanespimycin 1Sunitinib 1PT2385 1Oxygen-15 1Fluorodeoxyglucose F18 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × von Hippel-Lindau Disease × vatalanib × Clear all
NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Novartis

Phase 2 Completed
11 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡